CD274 and cancer: The recent success of therapeutic targeting of the immune checkpoint molecules, especially of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), has changed the paradigm of treatment for several types of cancer [10,12,13,14].